ClinicalTrials.gg
TerminatedNCT02966171Updated Nov 21, 2018

A Dose Escalation Study to Assess the Safety and Tolerability of HMPL-453 in Patients With Advanced Solid Malignancies

A Phase 1 interventional study of HMPL-453 in Solid Tumor, sponsored by Hutchison Medipharma Limited. Terminated at 4 sites in Australia. Open to participants aged 25 Years and older. Per ClinicalTrials.gov, last updated 2018-11-21.

Sponsored by Hutchison Medipharma Limited (part of HUTCHMED) · Phase 1, Interventional, and Treatment

Why this study was terminated
The study was terminated on 23AUG2018 for safety reasons.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
25 Years and older
Sex
All
01

Study summary

This is a first-time-in-human, phase I, open-label, dose-escalation study of HMPL-453 in patients with advanced or metastatic solid malignancies who have failed or are intolerable to standard therapies or for whom no standard therapies exist. There are preliminary two stages in this study: a dose-escalation stage (stage 1) and a dose-expansion stage (stage 2). We will decide whether to conduct stage 2 or not one month after the last patient included in stage 1.

Read the detailed description

Dose-escalation stage (stage 1): Patients participating in the dose-escalation stage will take a single dose of HMPL-453 on Day 1 and will be followed for one week for safety observations. After one week of observation, if no safety issues occur, patients can continue multiple dosing of HMPL-453 QD and start on the DLT assessment cycles. Each cycle consists of 28-days. Patients are required to draw blood samples for PK and safety analysis at specific time points during the treatment.

The 3+3 design will be employed for the dose escalation and MTD determination. To limit the number of patients being exposed to potentially ineffective doses, one patient will be enrolled and dosed in the initial dose cohort. If there are no DLT or \< 2 CTCAE grade 2 toxicities occur in the first treatment cycle, then the study will be escalated to the next dose cohort. Otherwise, the trial will revert to a standard 3+3 design.

Dose-Expansion Stage (Stage 2): This stage is to further evaluate the safety, tolerability, PD profile, and preliminary anti-tumor activity of HMPL-453 at the RP2D in approximately 10 patients with advanced solid tumor. Patients with FGFR dysregulated advanced solid tumors, including but not limited to, advanced gastric cancer, advanced urothelial bladder cancer, or advanced cholangiocarcinoma (patients with cancers of the gallbladder or ampulla of Vater are not eligible) are preferred to be enrolled.

Expansion stage will begin after dose-escalation stage is completed and the MTD/RP2D has been determined. Patients will receive HMPL-453 with 28-day treatment cycles until disease progression, death, intolerable toxicity, no longer benefiting from the study treatment per investigator's discretion, or withdrawal of consent, whichever comes first.

02

Conditions studied

  • Solid Tumor

Keywords

  • Advanced Solid Malignancies
03

In context

Lead sponsor

Hutchison Medipharma Limited is the lead sponsor of 68 studies on the registry; 1 is open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 2 (22%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • In the dose escalation stage, patients with locally advanced, or solid tumor who have failed, or intolerable to, standard therapies or for whom no standard therapies exist will be enrolled.
  • In the dose expansion stage, patients with locally advanced, or metastatic solid tumor and FGFR dysregulation who have failed or intolerable to standard therapies or no standard therapies exist are to be enrolled.
  • In the dose escalation stage: evaluable or according to Version 1.1. In the dose expansion stage: measurable disease according to RECIST Version 1.1.
  • of at least 12 weeks.
  • performance status of 0 or 1

Exclusion criteria

Exclusion Criteria:

  • Prior or current treatment with any selective FGFR inhibitor.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    HMPL-453

    Two strengths of HMPL-453 tablets (25 mg and 100 mg based on the free base) will be used for clinical studies. The drug products are coated tablets, which are packaged in white induction sealed HDPE bottles. HMPL-453 will be administered to patients as oral tablet(s) on a daily basis, untill disease progression, intolerable toxicity, or death. Dose levels are to be potentially tested in this study include 25, 50, 100, 200, 300, 400, and 500 mg/day.

    Drug: HMPL-453

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of DLTs by the NCI CTCAE v4.03

    Time frame: Cycle 1 (DLT assessment window, 28 days) of multiple dosing peroid

Secondary outcomes

  1. Incidence of AEs, clinically significant laboratory abnormalities, and electrocardiographic (ECG) changes and vital signs

    Time frame: from first dose to 30 days after last dose of study treatment

  2. maximum plasma concentration (Cmax)

    Time frame: from first dose to day 56 of multiple dosing peroid

  3. time to reach maximum concentration (Tmax)

    Time frame: from first dose to day 56 of multiple dosing peroid

  4. terminal half-life (t1/2)

    Time frame: from first dose to day 56 of multiple dosing peroid

  5. area under the concentration-time curve (AUC0-t)

    Time frame: from first dose to day 56 of multiple dosing peroid

  6. apparent clearance (CL/F)

    Time frame: from first dose to day 56 of multiple dosing peroid

  7. Serum phosphate level increases

    Time frame: from first dose to Day 21 of the last treatment cycle

  8. Objective response rate (ORR)

    Time frame: Every 8 weeks while being treated with HMPL-453 (expected average of 16 weeks)

  9. Duration of response (DoR)

    Time frame: Every 8 weeks while being treated with HMPL-453 (expected average of 16 weeks)

  10. Disease Control Rate (DCR)

    Time frame: Every 8 weeks while being treated with HMPL-453 (expected average of 16 weeks)

  11. Change in tumor size

    Tumor size is defined as the sum of the lengths of the longest diameters of the RECIST 1.1 target lesions (TLs). Percentage change in tumor size will be determined for patients with measurable disease at baseline and is derived at each visit by the percentage change in the sum of the diameters of TLs compared to baseline.

    Time frame: Every 8 weeks while being treated with HMPL-453 (expected average of 16 weeks)

  12. Progression free survival (PFS)

    Time frame: Every 8 weeks while being treated with HMPL-453 (expected average of 16 weeks)

Other outcomes

  1. FGFR genetic alterations status

    Dose Escalation stage (optional): to retrospectively determine the FGFR genetic alterations in tumor sections for the patients who have either a complete or partial response as per RECIST 1.1.

    Time frame: expected average of 16 weeks

  2. FGFR pathway inhibition by pERK

    Dose expansion stage (optional): explores the FGFR pathway inhibition in the fresh tumor samples pre- and after the treatment of HMPL-453.

    Time frame: from first dose to Day 15 of the first treatment cycle

07

Study locations

4 sites
  • St Vincent's Cancer Services
    Sydney, New South Wales 2010, Australia
  • Chris O'Brien Lifehouse
    Sydney, New South Wales 2050, Australia
  • Peninsula and Southeast Oncology
    Frankston, Victoria 3199, Australia
  • Monash Medical Centre
    Melbourne, Victoria 3168, Australia
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2017 to primary completion in Aug 2018, 19 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2016
First posted
Nov 17, 2016
StartActual
Jan 2017
Primary completionActual
Aug 23, 2018
CompletionActual
Aug 23, 2018
Last update
Nov 21, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02966171
Responsible party
Sponsor
First posted
Nov 17, 2016
Start date
Jan 2017
Primary completion
Aug 23, 2018
Completion
Aug 23, 2018
Last update
Nov 21, 2018

Study contacts

Weiss Yang
study director · Hutchison Medipharma Limited

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fanregratinib

Start the discussion